Cronos Group (NASDAQ:CRON – Get Free Report) issued its earnings results on Thursday. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.01, Zacks reports. Cronos Group had a return on equity of 4.85% and a net margin of 39.08%. The business had revenue of $63.45 million for the quarter, compared to analyst estimates of $51.15 million.
Here are the key takeaways from Cronos Group’s conference call:
- Cronos reported record Q3 net revenue, gross profit, and Adjusted EBITDA: revenue rose 75% year over year to $63.5 million, while Adjusted EBITDA reached $17.1 million.
- Canadian brands grew retail sales 41% year over year, versus 1% industry growth, with Spinach gaining share across vapes, flower, and pre-rolls; SOURZ remained the leading edible brand.
- Israel delivered its 11th consecutive quarter of record revenue, up 33%, and revenue in international markets outside Israel increased sevenfold to $13.2 million, led by Germany. Management cautioned that export timing can make international sales uneven from quarter to quarter.
- Cronos completed its CanAdelaar acquisition in the Netherlands, seeing long-term potential in introducing branded products and improving operations. Management expects price compression as supply ramps up and said expansion of the regulated experiment is possible but not something it is relying on.
- The company ended the quarter with $841 million in cash, restricted cash, investments, and deposits, up $14 million from Q2. Management noted possible Q4 softness in Canadian provincial-board purchases and said margins can vary by quarter.
Cronos Group Price Performance
CRON traded down $0.11 during trading hours on Friday, reaching $3.61. 1,315,929 shares of the stock traded hands, compared to its average volume of 1,264,931. The firm’s fifty day simple moving average is $3.30 and its two-hundred day simple moving average is $2.87. The company has a market cap of $1.32 billion, a price-to-earnings ratio of 18.05 and a beta of 0.96. Cronos Group has a fifty-two week low of $2.28 and a fifty-two week high of $3.91.
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on CRON shares. Wall Street Zen downgraded shares of Cronos Group from a “buy” rating to a “hold” rating in a research note on Saturday, August 15th. Zacks Research raised shares of Cronos Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 22nd. Weiss Ratings raised Cronos Group from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Finally, TD Securities reaffirmed a “buy” rating on shares of Cronos Group in a research note on Monday, September 28th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cronos Group presently has a consensus rating of “Buy” and an average target price of $2.30.
Key Cronos Group News
Here are the key news stories impacting Cronos Group this week:
- Positive Sentiment: Q3 net revenue rose 73% year over year on an organic, constant-currency basis, with the company reporting record net revenue, gross profit and adjusted EBITDA. Revenue of $63.45 million and earnings of $0.04 per share also exceeded analyst estimates of $51.15 million and $0.03, respectively. Cronos Group Reports 2026 Third Quarter Results
- Positive Sentiment: Growth was broad-based: Cronos posted record Canadian sales, a record quarter in Germany, and its 11th consecutive quarter of record net revenue in Israel. Its Spinach brand retained the top position in Canadian vapes and edibles, while the Canatolar acquisition expands its European reach. Q3 2026 Earnings Call Highlights
- Neutral Sentiment: The company said it reduced its share count, which can support per-share results, though the available reports do not quantify the effect. Cronos Group Reports 2026 Third Quarter Results
- Negative Sentiment: Despite beating estimates, Q3 earnings of $0.04 per share were below the $0.07 reported a year earlier. A separate valuation discussion also notes that the stock’s 93% three-year gain puts more focus on whether current earnings justify its valuation. Cronos Group Stock Looks Hard To Call Following Its 93% Run
Cronos Group Company Profile
Cronos Group Inc is a Canadian cannabinoid company focused on developing, producing and commercializing cannabis and cannabis-derived consumer products. The company serves adult-use and medical cannabis markets through a portfolio of brands and sells products such as dried flower, pre-rolls, vaporizers, edibles, oils and other cannabis formats, subject to applicable regulations.
Its brand portfolio has included Spinach, which is positioned primarily in the adult-use cannabis market, as well as Lord Jones and PEACE NATURALS.
Read More
- Five stocks we like better than Cronos Group
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.
